Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings.

Updated Phase 2 Tumor Response and Survival Data with ADVEXIN[R], INGN 225 and INGN 241 to Be Presented at ASCO and ASGT 

AUSTIN, Texas -- Introgen Therapeutics, Inc. (NASDAQ:INGN) and the Company's clinical collaborators will report updated Phase 2 clinical trial results for its lead cancer therapy product candidates at the upcoming annual meetings of The American Society of Clinical Oncology (ASCO) in Chicago and the American Society of Gene Therapy (ASGT) in Seattle.

"We have a stronger than ever, advancing pipeline of first-in-class cancer therapies generating exciting data that could change the way cancer is treated and fulfill the promise of molecularly targeted cancer therapy," said Robert E. Sobol, M.D., senior vice president of Medical and Scientific Affairs at Introgen. "We have multiple Phase 3 programs either underway or planned with the goal of bringing these therapies to market to provide new treatments for widely underserved patient populations that are effective, generally well tolerated and can be easily combined and act synergistically with standard therapies by or before the end of this decade."

ASCO

* Final results of a phase II trial of patients with extensive stage small cell lung cancer (ES-SCLC) immunized with wild type -p53 transduced dendritic cells after first-line chemotherapy, Abstract #3012: Poster presentation on Sun., June 3, from 2:00 - 6:00 p.m. in room S102a at McCormick Place, by lead author Alberto Chiappori, M.D., H. Lee Moffitt Cancer Center and Research Institute.

* Tumor response criteria and biomarkers associated with increased survival following adenoviral p53 gene therapy (ADVEXIN) in patients with recurrent squamous cell carcinoma of the head and neck, Abstract #6057: Poster presentation on Mon., June 4, from 1:00 - 5:00 p.m. at McCormick Place by lead author John Nemunaitis, M.D., Mary Crowley Medical Research Center and poster presentation by Robert Sobol, M.D., Introgen Therapeutics, Inc.

ASGT

* Role of the Immune System in Replicating Adenovirus Using a Permissive Immune Competent Syrian Hamster Model, William Wold, Ph.D., St. Louis University School of Medicine: Presentation on Thurs., May 31, from 9:30 - 11:30 a.m. at Washington State Convention Center during symposium titled "Cancer: Hot Topics in Cancer Gene Therapy"

* MDA-7 (INGN-241) Kills Chemoresistant Cancer Cells and Restores Chemosensitivity to Cisplatin, Abstract #197: Presentation during "Cancer: Apoptosis and Suicide" poster session on Thurs., May 31, from 5:00 - 8:00 p.m. at Washington State Convention Center by Rajagopal Ramesh, Ph.D., M. D. Anderson Cancer Center

* Effect of Pre-existing Anti-Adenovirus Immunity and Anti-Tumor Immunity on the Efficacy of Adenovirus Vectors in Immunocompetent Syrian Hamster Model, Abstract #668: Presentation during "Immune Responses to Adenoviral Vectors" poster session on Fri, June 1, from 5:15- 8:15 p.m. in Hall 4AB at Washington State Convention Center by Debanjan Dhar, St. Louis University School of Medicine

* Anticancer Activity of Oncolytic Adenovirus Vector Armed with IFN-alpha and ADP is Enhanced by Pharmacologically-Controlled Expression of TRAIL, Abstract #588: Presentation during "Cancer Immunotherapy II" poster session on Fri., June 1, 2007 from 5:15 - 8:15 p.m. in Hall 4AB at Washington State Convention Center by Elena V. Shashkova, VirRx, Inc.

* Clinical Experience with the mda-7/IL-24 Tumor Suppressor, Abstract # 380: Presentation during "Tumor Suppressor and Targeted Gene Therapy" poster session and oral presentation on Friday, June 1, 2007 at 8:45 a.m. at the Washington State Convention Center by Sunil Chada, Ph.D., Introgen Therapeutics, Inc.

About Introgen Therapeutics, Inc.

Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.

Statements in this release that are not strictly historical may be "forward-looking" statements, including those relating to Introgen's future success with its ADVEXIN, INGN 241, and INGN 007 clinical development programs. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen's operations and business environment, including Introgen's stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen's product candidates, the ability to obtain the appropriate regulatory approvals, Introgen's patent protection and market acceptance, as well as other risks detailed from time to time in Introgen's filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.

Editor's Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen's Website at: www.introgen.com.